RPCEC00000368
Recruiting
未知
Evaluation of the immune response generated after vaccination with CIMAvax-EGF using different maintenance schedules.
Center of Molecular Immunology (CIM)0 sites42 target enrollmentMay 12, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- on small cell lung cancer
- Sponsor
- Center of Molecular Immunology (CIM)
- Enrollment
- 42
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with a cytological / histological diagnosis of non\-small cell lung carcinoma in all stages IIIb and IV, of any sex and age equal to or greater than 18 years, who have completed at least 2 cycles of first\-line chemotherapy.
- •2\. Patients who have signed the informed consent for the research.
- •3\. Patients with clinical status criteria (ECOG) from 0 to 2\.
Exclusion Criteria
- •1\. Patients of childbearing potential who are not using an adequate method of contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms) while the treatment lasts.
- •2\. Pregnant, lactating or postpartum patients.
- •3\. Patients with uncontrolled intercurrent illnesses including, but not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes mellitus, arterial hypertension and psychiatric illnesses that imply the incompetence of the subject.
- •4\. Patients with brain metastases.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of immunological response following a revaccination with a non-conjugated pneumococcal vaccine boosted or not by a conjugated pneumococcal vaccine in splenectomised patients (SPLENEVAC-2)Asplenic patients at risk for invasive pneumococcal diseasesMedDRA version: 20.0Level: PTClassification code 10041642Term: SplenectomySystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2018-003068-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)56
Completed
Not Applicable
Evaluation of humoral immune response induced by a supplemental dose of inactivated poliovirus vaccine (IPV) administered intradermally or intramuscularly versus a dose of monovalent type 1 oral poliovirus vaccineISRCTN90744784Panacea Biotec Limited (India)1,000
Active, not recruiting
Not Applicable
Determination of immune response after sequential pneumococcal vaccination using the 7-valent conjugate pneumococcal and the 23-valent pneumococcal polysaccharide vaccine in renal transplant recipientsEUCTR2007-004590-25-ATMedical University of Vienna
Completed
Not Applicable
A study for evaluating the immune response by ingestion of fermented plant extractHealthy adultJPRN-UMIN000052021EP Mediate Co., Ltd.36
Completed
Not Applicable
A study for evaluating the immune response by ingestion of a fucoidan-containing food in adult males and females : a randomized, double blind, placebo-controlled, parallel-group trialJPRN-UMIN000024995TTC Co., Ltd.60